m-Chlorophenylpiperazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
m-Chlorophenylpiperazine
Accession Number
DB12110
Type
Small Molecule
Groups
Investigational
Description

m-Chlorophenylpiperazine has been used in trials studying the treatment of Alcoholism.

Structure
Thumb
Synonyms
  • 1-(3-chlorophenyl)piperazine
  • M-CPP
  • MCPP
External IDs
J227.960F / NSC-49307
Product Ingredients
IngredientUNIICASInChI Key
m-Chlorophenylpiperazine dihydrochlorideMY02G3EAXQ51639-49-7OSZCTRWSGNWWBL-UHFFFAOYSA-N
m-Chlorophenylpiperazine hydrochloride7IM2GS7ILV13078-15-4MHXPYWFZULXYHT-UHFFFAOYSA-N
Categories
UNII
REY0CNO998
CAS number
6640-24-0
Weight
Average: 196.677
Monoisotopic: 196.076726133
Chemical Formula
C10H13ClN2
InChI Key
VHFVKMTVMIZMIK-UHFFFAOYSA-N
InChI
InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2
IUPAC Name
1-(3-chlorophenyl)piperazine
SMILES
ClC1=CC(=CC=C1)N1CCNCC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 2C
agonist
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when m-Chlorophenylpiperazine is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when m-Chlorophenylpiperazine is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with m-Chlorophenylpiperazine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when m-Chlorophenylpiperazine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with m-Chlorophenylpiperazine.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when m-Chlorophenylpiperazine is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with m-Chlorophenylpiperazine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when m-Chlorophenylpiperazine is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with m-Chlorophenylpiperazine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with m-Chlorophenylpiperazine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0061008
KEGG Compound
C11738
PubChem Compound
1355
PubChem Substance
347828411
ChemSpider
1314
BindingDB
50001915
ChEBI
10588
ChEMBL
CHEMBL478

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentCocaine-Related Disorders1
Not AvailableRecruitingBasic ScienceBMI >30 kg/m2 / Eating Behavior1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.12 mg/mLALOGPS
logP2.07ALOGPS
logP2.15ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area15.27 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity56.05 m3·mol-1ChemAxon
Polarizability20.87 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-a6d6490a377499574773
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-dacdc382bd4b60551efd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-c498b22640780e85d0c5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-6188e12d6302f0aac6ad
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-0900000000-0307be5cc27e8b5e3d6e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0900000000-4f1ffdc6559ba8ef8ab0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0900000000-ffa868d7cd2f5dd55b0a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-036e27cc7151ed5587e2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-cf09b776cfded257a89e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-8119dafe7571a20d6ce8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udj-0900000000-0826be5530cb871f3576
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0900000000-a55042eda43832b42f68
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0900000000-c3dd0b695bc65a727bf0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0900000000-ce6c9c7155861aeb31be
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gb9-0900000000-04b37011a6b6e19ca424
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-1900000000-5ea27eb4735ba042f7d9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-04afb01877e4cfc97762
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-2391d33f985d617108cf
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f6t-0900000000-46eb898a4634d282ad5d

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Dialkylarylamines / Aniline and substituted anilines / Chlorobenzenes / Aryl chlorides / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Phenylpiperazine / N-arylpiperazine / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Chlorobenzene / Halobenzene / Monocyclic benzene moiety / Aryl halide / Aryl chloride
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
N-arylpiperazine, monochlorobenzenes (CHEBI:10588)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Gibson EL, Barnfield AM, Curzon G: Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects. Neuropharmacology. 1994 Mar-Apr;33(3-4):457-65. [PubMed:7984284]

Drug created on October 20, 2016 15:22 / Updated on June 04, 2019 07:32